Drug Patents owned by Eiger Biopharms

1. Drug name - ZOKINVY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8828356 EIGER BIOPHARMS Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
Oct, 2023

(10 months from now)

US7838531 EIGER BIOPHARMS Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
Jul, 2024

(1 year, 7 months from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 20, 2027
New Chemical Entity Exclusivity (NCE) Nov 20, 2025

Drugs and Companies using LONAFARNIB ingredient

Market Authorisation Date: 20 November, 2020

Treatment: Reducing the risk of mortality in hutchinson-gilford progeria syndrome (hgps)

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
50MG CAPSULE;ORAL Prescription
75MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in